Journal Information
Scientific Letter
Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis
El osimertinib como tratamiento del adenocarcinoma de pulmón con mutación positiva del EGFR complicado con dermatomiositis
Masahiro Yamasakia,
, Naoko Matsumotoa, Shota Nakanob, Kazuma Kawamotoa, Masaya Taniwakia, Yusuke Izumia, Masaya Otoharaa, Shinji Nabeshimac, Nobuyuki Ohashid, Noboru Hattoric
Corresponding author
a Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Naka-ku, Hiroshima, Japan
b Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Naka-ku, Hiroshima, Japan
c Department of Molecular and Internal Medicine, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan
d Ohashi Clinic, Naka-ku, Hiroshima, Japan